vTv Therapeutics (VTVT) Cash from Investing Activities (2014 - 2023)

vTv Therapeutics (VTVT) reported Cash from Investing Activities of $4.4 million for Q4 2023, up 6576.47% sequentially from -$68000.0 in Q4 2019.

vTv Therapeutics (VTVT) Cash from Investing Activities (2014 - 2023) Analysis & Trends

vTv Therapeutics (VTVT) has 6 years of Cash from Investing Activities data on file, last reported at $4.4 million in Q4 2023.

For the quarter ending Q4 2023, Cash from Investing Activities changed N/A year-over-year to $4.4 million; the trailing twelve-month figure through Dec 2023 stood at $4.4 million (changed N/A YoY), and the FY2023 full-year result was $4.4 million, up 21071.43% from the prior year.
Cash from Investing Activities advanced to $4.4 million in Q4 2023, from -$68000.0 in the prior quarter.
In the past five years, Cash from Investing Activities ranged from a high of $4.4 million in Q4 2023 to a low of -$68000.0 in Q4 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Cash from Investing Activities (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn	-45.51 Mn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn	-431.90 Mn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn	-428.90 Mn
7	Belite Bio	62.72 Bn	62.72 Bn	-	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn	-
9	Revolution Medicines	37.35 Bn	37.35 Bn	-	172.62 Mn
10	vTv Therapeutics	19.21 Mn	19.21 Mn	-	-

Download Data